ArticleDermatology and therapy2026
Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNemolizumab is a humanized monoclonal antibody that specifically inhibits the receptor for interleukin-31, the major pruritogen in atopic dermatitis (AD). While the patient profile associated with the early therapeutic response to nemolizumab in AD has been increasingly delineated, the characteristics of patients who benefit from long-term nemolizumab therapy remain unclear. This study aimed to identify early clinical features predicting long-term improvement in pruritus Visual Analog Scale (VAS) score among patients receiving nemolizumab.
methodsThis study included patients participating in two Japanese clinical trials (JP01 and JP02) who did not achieve a 50% improvement in pruritus VAS score (VAS50) at week 16 after initiation of nemolizumab treatment. Patients who achieved VAS50 at week 52 were classified as responders, and those who did not were nonresponders. A machine-learning decision tree model was developed using 213 candidate variables. Model performance was evaluated using the F
resultsAmong 118 eligible patients, the final model achieved an F
conclusionsMachine-learning identified straightforward and clinically applicable predictors of long-term nemolizumab efficacy in patients who did not have early VAS improvement. These findings may support decision-making for treatment continuation beyond week 16. TRIAL REGISTRATION NUMBER: JapicCTI-173740 (JP01), and JapicCTI-183894 (JP02).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.